Last updated on August 2018

Selenium Supplementation in Autoimmune Thyroiditis

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Autoimmune thyroiditis | Hashimoto's Disease
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Age 18 years.
  2. Serum-TPO-Ab 100 IU/mL measured within the last 12 months.
  3. Receiving LT4 treatment.
    • Serum-TSH 4.0 mU/L measured prior to treatment initiation
  4. Written informed consent.

Exclusion Criteria:

  1. Previous diagnosis of toxic nodular goitre, Graves' hyperthyroidism, post-partum thyroiditis or thyroid associated orbitopathy (TAO).
  2. Previous radioiodine therapy, anti-thyroid treatment or thyroid surgery.
  3. Previous diagnosis of non-melanoma skin cancer.
  4. Morbidity, rendering the participant unable to process patient reported outcomes or receive intervention during the trial.
  5. Systemic immunomodulatory medication.
  6. Other medication known to affect thyroid function.
  7. Pregnancy, breastfeeding, or planned pregnancy within 18 months.
  8. Allergy towards the components in the selenium or placebo pills.
  9. Intake of selenium supplementation 55 g/d.
  10. Unable to read or understand Danish.
  11. Lack of informed consent

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.